Preclinical toxicity testing: acute toxicity, sub-acute toxicity, and combined chronic and carcinogenicity testing as per OECD norms.

Preclinical toxicity testing is an essential component of drug development that helps identify the potential harmful effects of a drug or chemical substance before its use in humans. These studies provide important information regarding the safety profile of a substance, possible target-organ toxicity, dose-response relationship, and safe exposure levels. Toxicity testing is carried out using scientifically designed experimental models and internationally accepted guidelines, including those developed by the Organisation for Economic Co-operation and Development (OECD).

The present topic covers the basic principles and definitions of major preclinical toxicity studies, including acute toxicity, which evaluates harmful effects following a single dose or short-term exposure, and subacute or repeated-dose toxicity, which helps identify toxic effects following repeated administration over a specified period. It also includes chronic toxicity and carcinogenicity testing, which assess the long-term adverse effects of continuous exposure and a substance's potential to produce tumours. The combined chronic toxicity/carcinogenicity study provides valuable information on both long-term systemic toxicity and carcinogenic potential.

A clear understanding of OECD toxicity testing guidelines, including important test guideline numbers and their applications, is highly relevant for pharmacy students and aspirants preparing for UPSC Drug Inspector, GPAT, NIPER, AIIMS Pharmacist, Railway Pharmacist, SSC, ESIC, and State Pharmacist examinations.

Dr. Alok Singh

The following MCQs with answers and short explanations will help you revise important concepts, OECD guidelines, and frequently asked competitive examination points related to preclinical toxicity testing.

https://drive.google.com/file/d/1VpAxSAqx0ko55fNvkbsDa5guu2zBVgNX/view?usp=drive_link